Disease relevance of Erucylphosphocholine

• Erucylphosphocholine-induced apoptosis in glioma cells: involvement of death receptor signalling and caspase activation [1].
• MAP kinase pathways involved in glioblastoma response to erucylphosphocholine [2].
• Erucylphosphocholine (ErPC) is a promising candidate for the treatment of human brain tumors [3].
• The in vitro effects of the intravenously applicable erucylphosphocholine (ErPC) on proliferation, viability, morphology and cell cycle distribution of a rat glioma, four human astrocytoma/glioblastoma and a human medulloblastoma cell line were analyzed daily after continuous drug-exposure for up to six days [4].
• Toxicity study of erucylphosphocholine in a rat model [5].

High impact information on Erucylphosphocholine

• Intracellular mediators of erucylphosphocholine-induced apoptosis [6].
• In addition, IBP knockdown prevented processing of the caspase 3 component of the apoptosis cascade by the erucylphosphocholine congener, erucylphospho-N,N,N-trimethylammonium [7].
• Moreover, activity of the survival kinase PKB/Akt was downregulated upon treatment with ErPC/ErPC3 alone or in combination with ionizing radiation [8].
• BACKGROUND AND PURPOSE: The membrane-targeted apoptosis modulators erucylphosphocholine (ErPC) and erucylphosphohomocholine (ErPC3) induce apoptosis in highly apoptosis resistant malignant glioma cell lines and enhance radiation-induced cell death and eradication of clonogenic tumor cells in vitro [8].
• Erucylphosphocholine (ErPC) is a promising antineoplastic drug for the treatment of malignant brain tumors [2].

Chemical compound and disease context of Erucylphosphocholine

• Induction of differentiation and tetraploidy by long-term treatment of C6 rat glioma cells with erucylphosphocholine [9].

Biological context of Erucylphosphocholine

• Erucylphosphocholine: pharmacokinetics, biodistribution and CNS-accumulation in the rat after intravenous administration [10].
• Therefore we evaluated the clinical pharmacology of erucylphosphocholine (ErPC), the first derivative of the APC family suitable for intravenous administration with strong antineoplastic activity, in vitro and in vivo in rats [10].

Anatomical context of Erucylphosphocholine

• The synthetic phospholipid derivative erucylphosphocholine (ErPC) is a potent inducer of apoptosis in human tumor cell lines [11].
• BACKGROUND: Erucylphosphocholine (ErPC) has been shown to exert strong antineoplastic effects against various brain tumor cell lines in vitro [12].
• High EPC concentrations were found in the small intestine (628 nmol/g) [13].
• PURPOSE: To investigate the effect of intraocular erucylphosphocholine (ErPC) on the retina, the retinal pigment epithelium (RPE), and the choroid in an in vivo rat model [5].

Gene context of Erucylphosphocholine

• The prototype of i.v. injectable APC, erucylphosphocholine, was more active against BCR-ABL-positive cell lines than the two reference APC [14].
• Erucylphosphocholine-induced apoptosis in chemoresistant glioblastoma cell lines: involvement of caspase activation and mitochondrial alterations [15].
• Downregulation of Apaf-1 and caspase-3 by RNA interference in human glioma cells: consequences for erucylphosphocholine-induced apoptosis [16].

References